Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2011 Financial Results and Highlights
Date:5/5/2011

SAN DIEGO, May 5, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C, today reported its program highlights and financial results for the first quarter ended March 31, 2011.

"The ANA598 Phase IIb study currently underway will expand the profile of ANA598 in important ways," said Steve Worland, Ph.D., President and CEO of Anadys.  "We expect to increase the ANA598 safety database by approximately 200 patients, with dosing through 24 weeks completed by year-end, and to characterize ANA598's activity in combination with pegylated interferon and ribavirin in treatment-experienced patients.  The acquisition of these data should significantly enhance ANA598's readiness for Phase III activities."

Development Program Highlights

  • ANA598 Phase IIb Study.  During the first quarter, Anadys commenced dosing HCV patients in an ongoing Phase IIb study in which ANA598 is being tested in combination with interferon and ribavirin in both treatment-naive patients and patients who failed a prior course of therapy with interferon and ribavirin.  Approximately 275 patients are expected to be enrolled in the study.  The primary endpoint of the study is Sustained Virological Response 24 weeks after patients complete treatment, known as SVR24.  The Company expects to receive antiviral response data through 12 weeks for all patients, including the 8 week timepoint used for response-guided therapy in treatment-naive patients, in the third quarter of 2011.  Antiviral response data through 24 weeks are expected in the fourth quarter of 2011.  
  • ANA773 Phase IIa Study.  The Company is preparing to commence during the second quarter a 28-day study of ANA773 in combination with riba
    '/>"/>

  • SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
    2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
    3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
    4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
    5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
    6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
    7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
    8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
    9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
    10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
    11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/27/2015)... 2015 E-QURE, Corp. (OTCQB: EQUR), ... the development and commercialization of its Bio-electrical Signal Therapy ... the noninvasive treatment of hard to heal chronic wounds, ... Cap Research http://scr.zacks.com issued a quarterly update ... Zacks, research update, E-QURE Corp "…has a compelling story ...
    (Date:5/27/2015)... -- Medical Device Contract Manufacturing - new ... Where is the market for medical ... prospects for this market and medical device ... shows you potential revenues and other trends to 2025, ... page report provides 127 tables, charts, and graphs. Discover ...
    (Date:5/27/2015)... CITY , May 27, 2015  Foundation Health ... surgeries and related ancillary services, announced today it will ... held June 1-3, 2015 at Luxe Sunset Boulevard Hotel, ... be presenting on Tuesday, June 2 nd at ... To schedule a one-on-one meeting please contact LD Micro. ...
    Breaking Medicine Technology:Zacks Investment Small Cap Research Issues Quarterly Update on E-QURE 2Zacks Investment Small Cap Research Issues Quarterly Update on E-QURE 3Medical Device Contract Manufacturing Market Forecast 2015-2025 2Medical Device Contract Manufacturing Market Forecast 2015-2025 3Medical Device Contract Manufacturing Market Forecast 2015-2025 4Medical Device Contract Manufacturing Market Forecast 2015-2025 5Medical Device Contract Manufacturing Market Forecast 2015-2025 6Medical Device Contract Manufacturing Market Forecast 2015-2025 7
    ... Landauer, Inc. (NYSE: LDR) announced today that ... of $0.55 per share for the second quarter of fiscal ... shareholders of record on March 9, 2012. ... technical and analytical services to determine occupational and environmental radiation ...
    ... 2012  In an effort to maximize business impact and ... research leaders must constantly evaluate the manner in which ... understand the optimal balance of external contract employees in ... quickly changing healthcare industry. To identify innovative ...
    Cached Medicine Technology:Current Study Offers Window into Automation & Outsourcing Practices Within Top Pharmaceutical Market Research Groups 2
    (Date:5/27/2015)... 2015 CompanionDx announced that ... genomic analysis in personalized cancer therapy: Non-small cell lung ... Society of Clinical Oncology (ASCO) as part of their ... , The molecular and clinical data used for the ... database. The study reports improved patient outcomes from a ...
    (Date:5/27/2015)... On June 5, Plan B [the ... with LifeSource to host Donate Your Break, a public ... a LifeSource donor coach outside of 116 W. Illinois ... Demand for whole blood units is highest for LifeSource, ... months. LifeSource requires approximately 1,000 donations per day to ...
    (Date:5/27/2015)... This is a professional and ... Omega-3 industry. The report provides a basic overview ... industry chain structure. The Omega-3 market analysis is ... competitive landscape analysis, and key regions development status. ... Company, Seadragon Marine Oils, Norwegian Fish Oil, Croda ...
    (Date:5/27/2015)... Meadows, IL (PRWEB) May 27, 2015 ... release of its SonarMD Platform, a first-of-its ... monitoring and managing patients with chronic gastrointestinal ... Kosinski, MD, MBA, the application allows physicians ... visits through the ongoing use of electronic ...
    (Date:5/27/2015)... “Heroin has never been more plentiful or ... coming from,” says Harford County Sheriff Jeff Gahler, as quoted ... the surging heroin related incidents in Baltimore, police resources are ... prevent heroin addiction and subsequent abuse before it turns into ... Baltimore is a drug and alcohol rehab facility specializing in ...
    Breaking Medicine News(10 mins):Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3Health News:Donate Your Break and Save Lives at the River North Blood Drive 2Health News:Omega-3 Market: Global 2015 Analysis & 2020 Forecasts on Market Size 2Health News:SonarMD™, LLC, Launches Game-Changing, IBD Population Health Management Platform 2Health News:The Price of Heroin in Baltimore Drops, Surging Use and Causing Rife Overdose Deaths 2Health News:The Price of Heroin in Baltimore Drops, Surging Use and Causing Rife Overdose Deaths 3
    ... Service Provider Chooses SonicWALL to Satisfy Business Need ... SonicWALL, Inc. (Nasdaq: SNWL ... announced that ZirMed, Inc., a leader in revenue ... Louisville, Kentucky, has implemented a SonicWALL(R) E-Class NSA ...
    ... Clarient, Inc. (Nasdaq: CLRT ... resource for pathologists, oncologists and the pharmaceutical industry, today ... renewed, expanded and extended its senior subordinated revolving credit ... SFE ), Clarient,s majority shareholder."In the current market ...
    ... medical equipment supplier, now sells its DRE Integra AV-S with a ventilator ... patients attempt to breathe spontaneously. , ... (Vocus) March 3, 2009 -- ... by Business First of Louisville, continues expanding its DRE Integra AV-S ...
    ... releases the first in a series of residential vacuum cleaner reviews ... , ... Boise, Idaho (Vocus) March 3, 2009 -- Before spending hundreds of ... the market, savvy shoppers turn to the Internet to research their choices. ...
    ... incidence of obesity-induced type 2 diabetes mellitus continues to ... obesity can completely eliminate all manifestations of diabetes. In ... The American Journal of Medicine , investigators analyzed ... showed that 78.1% of diabetic patients had complete resolution ...
    ... that helps trigger autoimmunity could lead to new treatments ... kill thousands of children annually, according to researchers. , ... has discovered genetic evidence that two distinct molecular ... a vitally important cell type in limiting undesirable immune ...
    Cached Medicine News:Health News:SonicWALL Delivers Flexible High-Performance Threat Management for ZirMed 2Health News:SonicWALL Delivers Flexible High-Performance Threat Management for ZirMed 3Health News:Clarient Renews and Expands Mezzanine Credit Facility With Safeguard 2Health News:Clarient Renews and Expands Mezzanine Credit Facility With Safeguard 3Health News:Clarient Renews and Expands Mezzanine Credit Facility With Safeguard 4Health News:DRE AV-S Ventilator Now Has Multiple Spontaneous Breathing Modes 2Health News:DRE AV-S Ventilator Now Has Multiple Spontaneous Breathing Modes 3Health News:DRE AV-S Ventilator Now Has Multiple Spontaneous Breathing Modes 4Health News:Shopping for a Vacuum Cleaner? Know What You're Buying! Internet Site and Rating System Can Help 2Health News:Shopping for a Vacuum Cleaner? Know What You're Buying! Internet Site and Rating System Can Help 3Health News:Study shows potential for resolving type 2 diabetes with bariatric surgery 2Health News:Genetic evidence points to potential therapeutic bypass for autoimmune process 2Health News:Genetic evidence points to potential therapeutic bypass for autoimmune process 3
    ... Ruschelit® PVC. 2 eyes, oral. ... patient age. X-ray opaque line. Graduated. ... access. Designed to reduce kinking of ... curvature. Thermosensitive Ruschelit® PVC adapts to ...
    ... PVC. 2 eyes, oral. Marked with ... X-ray opaque line. Graduated. Single use. ... reduce kinking of the tube by ... adapts to the anatomical situation at ...
    ... Slick Set® Tube with stylet inside. ... quality cuffed Rusch endotracheal tube with ... to use saving you time and ... coded for easy identification and has ...
    Ruschelit® PVC. Murphy eye-nasoral. Black positioning ring. High volume/low pressure cuff. X-ray opaque line. Graduated. Single use....
    Medicine Products: